Terms ending in 2034
Every in-force patent on CSL Behring GmbH's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,534,029 | Method of Purifying Proteins In force · High confidence | CSL Behring AG | In force | High confidence | |
| US 10,286,047 | Treatment and Prevention of Remote Ischemia-Reperfusion Injury In force · Medium confidence | CSL Behring GmbH and Universitaet Bern | In force | Medium confidence | |
| US 10,973,891 | Treatment and Prevention of Remote Ischemia-Reperfusion Injury In force · High confidence | CSL Behring GmbH and Universitaet Bern | In force | High confidence | |
| US 10,221,233 | Compositions Comprising Secretory-Like Immunoglobulins In force · High confidence | CSL Behring AG | In force | High confidence | |
| US 10,441,631 | Therapeutic Agent for Amniotic Fluid Embolism In force · High confidence | CSL Behring GmbH | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.